We distribute our research widely to institutional and retail investors through various channels, including our proprietary database, website, and other platforms (such as Bloomberg, Thomson Reuters and Factset).

We are fully MiFID II compliant. Our research is paid for by our corporate clients, and we do not carry out any execution business.

Published reports can be obtained by searching our Research Library below, or directly from the relevant Company Pages.

Advanced search
Date range (dd-mm-yyyy)

Hutchison China MediTech

China approval clears Sulanda in epNET

Update | 04 January 2021

Redx Pharma

Funding secured to support next chapter of growth

Update | 04 January 2021

Mereo BioPharma

Setrusumab partnered with Ultragenyx

Lighthouse | 18 December 2020

Nexstim

Planning the next phase of growth

Update | 10 December 2020

Mereo BioPharma

Targeting TIGIT thoughtfully

Update | 09 December 2020

Redx Pharma

£25.5m placing extends runway to end-2022

Lighthouse | 02 December 2020

Nexstim

€0.9m prototype research project signed

Lighthouse | 18 November 2020

Hutchison China MediTech

Canada Pension Plan invests $100m at $30 per ADS

Lighthouse | 17 November 2020

Scancell

Redmile funding releases the brakes

Update | 17 November 2020

Allergy Therapeutics

Innovative G309 exploratory grass trial starts

Lighthouse | 26 October 2020
< 5 6 7 8 9 10 11 12 13 14 >
314 results found.